Antiplatelet therapy following cardiac valve replacement-a comparative study of aspirin and ticlopidine

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Hematology

Background:

• Antiplatelet agents like aspirin and ticlopidine are crucial for preventing thromboembolism in patients with cardiac valve replacements.
• Warfarin is concurrently administered to maintain specific therapeutic ranges (Thrombotest 10-25%, PT-INR 1.6-3.0).

Purpose of the Study:

• To compare the clinical efficacy and safety of daily low-dose aspirin versus ticlopidine in patients following cardiac valve replacement.
• To evaluate the incidence of thromboembolic events and hemorrhagic complications in both treatment groups.

Main Methods:

• A prospective study involving 100 patients undergoing aortic or mitral valve replacement.
• Patients were randomized to receive either daily aspirin (81 mg) or ticlopidine (300 mg) for a mean follow-up of approximately 52 months.
• Thromboembolism and hemorrhagic complication rates were recorded. Laboratory parameters including liver function tests and lipid profiles were monitored.

Main Results:

• Both aspirin and ticlopidine groups exhibited low incidences of thromboembolism (1.0/100 patient-years for ticlopidine, 1.9/100 patient-years for aspirin).
• Hemorrhagic complication rates were similar between groups (2.9 for ticlopidine, 2.3 for aspirin).
• Ticlopidine significantly reduced ADP-induced platelet aggregation, while no significant differences in other clinical outcomes or adverse reactions were noted between the two agents.

Conclusions:

• Both aspirin and ticlopidine are safe and effective antiplatelet therapies for patients with cardiac valve replacements.
• While ticlopidine demonstrates superior inhibition of platelet aggregation, clinical outcomes regarding thromboembolism and bleeding are comparable to aspirin in this patient cohort.